Clinical translation of ferumoxytol‐based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population

Purpose To assess the feasibility of acquiring vessel size imaging (VSI) metrics using ferumoxytol injections and stock pulse sequences in a multicenter Phase I trial of a novel therapy in patients with advanced metastatic disease. Methods Scans were acquired before, immediately after, and 48 h afte...

Full description

Saved in:
Bibliographic Details
Published in:Magnetic resonance in medicine Vol. 77; no. 2; pp. 814 - 825
Main Authors: Fredrickson, Jill, Serkova, Natalie J., Wyatt, Shelby K., Carano, Richard A.D., Pirzkall, Andrea, Rhee, Ina, Rosen, Lee S., Bessudo, Alberto, Weekes, Colin, de Crespigny, Alex
Format: Journal Article
Language:English
Published: United States Wiley Subscription Services, Inc 01.02.2017
Subjects:
angiogenesis
Animals
Blood vessels
Contrast agents
Contrast Media - metabolism
DCE‐MRI
Feasibility studies
Ferrosoferric Oxide - metabolism
Humans
Image acquisition
Image Processing, Computer-Assisted - methods
Injection
Liver
Magnetic resonance imaging
Magnetic Resonance Imaging - methods
Medical imaging
Metastases
Mice
Mice, Nude
Muscles
Neoplasms - diagnostic imaging
Neoplasms - metabolism
Neoplasms, Experimental - diagnostic imaging
Neuroimaging
Patients
tumor
Tumors
USPIO
vessel size
VSI
Xenografts
Xenotransplantation
vessel size
DCE-MRI
USPIO
VSI
angiogenesis
tumor
ISSN:0740-3194, 1522-2594, 1522-2594
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To assess the feasibility of acquiring vessel size imaging (VSI) metrics using ferumoxytol injections and stock pulse sequences in a multicenter Phase I trial of a novel therapy in patients with advanced metastatic disease. Methods Scans were acquired before, immediately after, and 48 h after injection, at screening and after 2 weeks of treatment. ΔR2, ΔR2*, vessel density (Q), and relative vascular volume fractions (VVF) were estimated in both normal tissue and tumor, and compared with model‐derived theoretical and experimental estimates based on preclinical murine xenograft data. Results R2 and R2* relaxation rates were still significantly elevated in tumors and liver 48 h after ferumoxytol injection; liver values returned to baseline by week 2. Q was relatively insensitive to changes in ΔR2*, indicating lack of dependence on contrast agent concentration. Variability in Q was higher among human tumors compared with xenografts and was mostly driven by ΔR2. Relative VVFs were higher in human tumors compared with xenografts, while values in muscle were similar between species. Conclusion Clinical ferumoxytol‐based VSI is feasible using standard MRI techniques in a multicenter study of patients with lesions outside of the brain. Ferumoxytol accumulation in the liver does not preclude measurement of VSI parameters in liver metastases. Magn Reson Med 77:814–825, 2017. © 2016 International Society for Magnetic Resonance in Medicine
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0740-3194
1522-2594
1522-2594
DOI:10.1002/mrm.26167